Allakos Reports Third Quarter 2019 Financial Results
12 nov. 2019 16h01 HE
|
Allakos Inc.
REDWOOD CITY, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast...
Allakos Announces Multiple Presentations from Its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2019 Annual Scientific Meeting
28 oct. 2019 09h01 HE
|
Allakos Inc.
REDWOOD CITY, Calif., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today...
Allakos Announces Upsizing and Pricing of Public Offering of Common Stock
06 août 2019 22h18 HE
|
Allakos Inc.
REDWOOD CITY, Calif., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related...
Allakos Announces Proposed Public Offering of Common Stock
05 août 2019 16h29 HE
|
Allakos Inc.
REDWOOD CITY, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related...
Allakos Reports Second Quarter 2019 Financial Results
05 août 2019 07h15 HE
|
Allakos Inc.
REDWOOD CITY, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related...
Allakos Announces AK002 Met All Prespecified Primary and Secondary Endpoints in Phase 2 Randomized, Double-Blind, Placebo-Controlled Study in Patients with Eosinophilic Gastritis (EG) and/or Eosinophilic Gastroenteritis (EGE)
05 août 2019 07h00 HE
|
Allakos Inc.
Primary efficacy endpoint met with 95% reduction in gastrointestinal tissue eosinophils vs. 10% increase on placebo (p < 0.0001)Treatment response secondary endpoint met with 69% of AK002 treated...
Allakos Reports First Quarter 2019 Financial Results
08 mai 2019 08h01 HE
|
Allakos Inc.
REDWOOD CITY, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today...
Allakos Announces Positive Results with AK002 in Patients with Severe Allergic Conjunctivitis
07 mai 2019 16h01 HE
|
Allakos Inc.
-- Substantial reduction of patient reported symptoms and physician assessed signs and symptoms -- -- Improvements also observed in atopic dermatitis, asthma and allergic rhinitis -- -- Conference...
Allakos Reports Fourth Quarter and Full Year 2018 Financial Results and 2018 Corporate Highlights
14 mars 2019 16h01 HE
|
Allakos Inc.
REDWOOD CITY, Calif., March 14, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today...
Allakos Announces Positive Phase 1 Results with AK002 in Indolent Systemic Mastocytosis
19 févr. 2019 08h00 HE
|
Allakos Inc.
REDWOOD CITY, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today...